Genespire Appoints Karen Aiach Pignet As Chief Executive Officer

Sep 12, 2024•11 months ago

Position

Chief Executive Officer

Company

Genespire

Karen Aiach-Pignet

MilanBiotechnologyHealth Care

Description

Genespire appoints Karen Aiach-Pignet as Chief Executive Officer to bolster its position as a leader in in-vivo lentiviral gene therapy. Karen joins as the company progresses lead candidate, GENE202, for the treatment of methylmalonic acidemia (MMA) into clinical development.

Company Information

Company

Genespire

Location

Milan, Lombardy, Italy

About

Genespire is a biotechnology company focused on the development of durable and transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners.

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months